secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2022-07-28T23:59:59+00:00
Accession:  0000078003-22-000091
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer Q2 revenue $27.7B record; adj. EPS $2.04 (+92%); raises FY guidance $0.24
--------------------------------------------------------------------------------

- Q2 revenue $27.7B (+47% YoY, +53% operational); Paxlovid contributed $8.1B, Comirnaty +20% operationally.
- Reported diluted EPS $1.73 (+77%); adjusted diluted EPS $2.04 (+92%), beating expectations.
- Raised FY2022 adj. EPS guidance to $6.30-6.45 (lower end up $0.05); revenue reaffirmed $98-102B.
- H1 capital: $4.5B dividends, $2B share buybacks; completed $6.3B Arena acquisition; announced $13.3B Biohaven deal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800322000091/0000078003-22-000091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800322000091/pfe-20220728.htm
  HTML page:      https://secwatch.observer/filing/0000078003-22-000091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer